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Introduction
Accurate classification is a requisite in the diagnosis, 
treatment and prognostication of cancer. Historically 
cancers have been classified according to the anatomic 
site of origin and histologic appearance, with the broad 
assumption that cancers from the same origin share 
common pathogenic processes. However, morphologically 
similar cancers can have widely variable clinical course and 
response to the same treatment, indicating fundamental 
differences in the pathogenic processes that drive each 
cancer. As cancer arises from distinct alterations in genetic 
and epigenetic events that culminate in transformed cellular 
behavior, being able to identify the crucial events that 
drive each cancer should ideally help optimize treatment 
decisions and improve patient outcomes, which are the 
principal goals of “personalized oncology”. The emergence 
of high throughput molecular tools in the past two decades 
including mRNA microarray, next generation DNA and 
RNA sequencing, methylation array and various proteomic 
tools have brought us closer towards these goals. We are 
now able to comprehensively visualize the salient genomic 
characteristics, gene expression profiles and proteomic 
information of each cancer case and start categorizing them 
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into “molecular” subtypes, which theoretically should better 
reflect the biology and behavior of each cancer. In fact, 
the past decade has seen an explosion of cancer genomic 
and transcriptomic analyses, and tremendous efforts to 
sub-categorize each cancer type based on these molecular 
features. Though still at its infancy, this new way of cancer 
classification holds promise to allow more refined clinical 
trial designs, more optimal patient allocation to targeted 
therapeutics, and prognostication, which will ultimately 
help both the patients and treating physicians.
In this article, we have reviewed the most recent 
landmark literature in molecular analysis and/or subtyping 
of major gastrointestinal cancers. These include esophageal 
squamous cell carcinoma (ESCC), gastric adenocarcinoma, 
pancreatic ductal adenocarcinoma (PDAC), hepatocellular 
carcinoma (HCC), gallbladder cancer (GBC) and colorectal 
cancer (CRC). More attention will be paid towards gastric, 
pancreatic ductal and colorectal adenocarcinoma since these 
cancers are more common and best studied.
Overview of molecular landscape and 
classifications of GI cancers
Gastric cancer (GC)
GC, which consists predominantly of adenocarcinoma, is 
the fifth most common cancer globally, and third leading 
cause of cancer deaths in 2012 (1). The first and most 
comprehensive molecular characterization of gastric 
adenocarcinoma was reported by the Cancer Genome 
Atlas Research Network (2). In this study, 295 treatment 
naïve primary gastric adenocarcinoma samples were 
characterized using six different molecular platforms 
including array-based somatic copy number analysis, whole-
exome sequencing (WES), array-based DNA methylation 
profiling, messenger RNA sequencing, microRNA (miRNA) 
sequencing and reverse-phase protein array. Integrated 
analysis of data from the platforms identified four distinct 
subtypes. Notably, no survival or racial differences were 
found among patients from each subgroup. 
(I) Epstein-Barr virus-infected (EBV, 9% samples): 
signified by high EBV burden, extensive DNA 
promoter hypermethylation (including universal 
CDKN2A promoter hypermethylation), frequent 
PIK3CA (80%), ARID1A (55%) and BCOR (23%) 
mutations, amplification of 9p24.1 locus (15%) 
containing genes encoding JAK2, PD-L1 and PD-L2. 
These data suggest potential therapeutic role for PI3K 
inhibitors, JAK2 inhibitors and immune checkpoint 
antagonists in this subgroup. EBV-GC were mostly 
located in the gastric fundus or body (62%) and more 
frequently found in male patients (81%).
(II) Microsatellite instability (MSI, 22% samples): signified 
by hypermutated genome and DNA hypermethylation 
(including MLH1 promoter hypermethylation). 
Mutations in PIK3CA, EGFR, ERBB2, and ERBB3 
were seen. MSI-GC tumors were diagnosed at an 
older age (median age 72 years), with a slightly higher 
prevalence in female patients (56%).
(III) Genomically stable (GS, 20% samples): signified by 
tumors with low somatic copy-number aberrations. 
GS-GC is enriched for CDH1 mutations (37%), 
which underlie hereditary diffuse GC syndrome, and 
either RHOA mutations or CLDN18-ARHGAP 
rearrangements (30%, mutually exclusive) which 
may enhance invasiveness and disrupt intercellular 
cohesion and contribute to the diffuse histology found 
in 73% of this subtype. GS-GC was diagnosed more 
frequently in younger patients (median age 59 years).
(IV) Chromosomal instability (CIN, 50% samples): 
signified by high somatic copy-number aberrations. 
High frequency of TP53 mutations (73%), genomic 
amplifications of genes in the receptor tyrosine 
kinase—Ras pathway including VEGFA, EGFR 
(10%), ERBB2 (24%), ERBB3 (8%), c-Met (8%), 
amplification of genes encoding cell cycle mediators, 
such as CCNE1, CCND1 and CDK6. These 
findings suggest potential use of many targeted 
agents towards this subtype. CIN-GC is found more 
frequently in the gastroesophageal junction/cardia 
(65%) and exhibits an intestinal histology.
Another major study was from the Asian Cancer 
Research Group (ACRG) (3,4). In this study, 300 GC were 
profiled using gene expression, genome-wide copy number 
microarray and targeted sequencing, yielding four distinct 
molecular subtypes. Importantly, each molecular subtype is 
associated with distinct prognosis.
(I) MSI-high (22.7% or 68/300 cases): this subtype 
occurred frequently in the antrum (75%), with 
>60% of cases exhibiting the intestinal subtype, and 
more than half of the cases diagnosed at early stages 
(I/II). This subtype had the best prognosis, and 
was associated with the presence of hypermutation, 
in addition to mutations in genes such as KRAS 
(23.3%), the PI3K-PTEN-mTOR pathway (42%), 
ARID1A (44.2%) and ALK (16.3%). 
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(II) Microsatellite stable/epithelial-mesenchymal 
transition (MSS/EMT, 15.3% or 46/300 samples): 
this subgroup was found to occur at a significantly 
younger age with the majority diagnosed with diffuse-
type histology and at advanced stages (III/IV). This 
subtype had the worst overall prognosis and a 
higher chance of recurrence compared to the MSI 
subgroup. 
(III) Microsatellite stable/epithelial/TP53 intact (MSS/
epithelial/TP53+, 26.3% or 79/300 samples): EBV 
infection occurred predominantly in this subgroup 
compared to other groups. This subtype had the 
second-best prognosis followed by MSI.
(IV) Microsatellite stable/epithelial/TP53 loss (MSS/
epithelial/TP53−, 35.7% or 107/300 samples): 
tumors falling under this subgroup had a less 
favorable prognosis compared to MSI and MSS/
epithelial/TP53+. As expected, this subgroup had 
the highest rate of TP53 mutations (60%).
The ACRG work (3,4) supplemented the TCGA 
analysis (2) by introducing TP53 activity and EMT in 
the classification. The two studies had similarities and 
differences. The MSI tumors were found in both datasets, 
and there was some overlap between GS, EBV+, and CIN 
subgroups defined by TCGA and MSS/EMT, MSS/TP53+, 
and MSS/TP53− of the ACRG respectively. However, several 
differences in terms of molecular mechanisms, driver genes 
and prognosis were observed between the two cohorts.
PDAC
PDAC is the fourth leading cause of cancer death in the United 
States and is projected to be the second by 2020 (5). The 
overall 5-year survival of PDAC is 7% (6). The extremely 
poor prognosis of PDAC highlights the urgent need to 
understand and target the molecular aberrations that 
drive this disease. Collisson et al. (7) first classified micro-
dissected pancreatic adenocarcinoma samples using gene 
expression analysis into three subtypes:
(I) Classical subtype: this subtype is characterized 
by high expression of adhesion-associated and 
epithelial genes, overexpression of GATA-binding 
protein 6 (GATA6), higher KRAS mRNA level and 
dependence on KRAS, more sensitivity to erlotinib 
and best survival outcomes.
(II) Quasimesenchymal (QM) subtype: this subtype is 
characterized by high expression of mesenchyme-
associated genes, more sensitivity to gemcitabine and 
has the worst survival outcomes of all three subtypes.
(III) Exocrine-like subtype: as the name implies, this 
subtype has the highest presence of tumor cell-
derived digestive enzyme genes. 
In a more elaborate study, Waddell et al. performed 
whole-genome sequencing (WGS) and copy-number 
variation (CNV) analysis of 100 PDACs. Based on structural 
variations, four subtypes were proposed (8).
(I) Stable subtype (subtype 1): accounts for 20% of 
samples, contains <50% structural variation events. 
Point mutations of KRAS, SMAD4, and telomere 
length in this subtype was not different compared 
to other subtypes.
(II) Locally rearranged subtype (subtype 2): accounts 
for 30% of all samples. About 1/3 of these samples 
showed focal regions of gain/amplifications, leading 
to copy number gain of genes including KRAS, SOX9, 
GATA6, and at a lower prevalence (1–2% of patients) 
of targetable mutations such as ERBB2, MET, CDK6, 
PIK3CA and PIK3R3. The remaining 2/3 of this 
subtype contained complex genomic events.
(III) Scattered subtype (subtype 3): 36% of samples 
belonged to this subtype with an intermediate 
range of non-random chromosomal alterations and 
<200 structural variation events.
(IV) Unstable subtype (subtype 4): accounts for 14% of 
samples, characterized by a large number (>200, 
maximum 558) of structural variations suggestive 
of defects in DNA stability. This subtype showed 
strong relationship with mutations in BRCA 
pathway genes (BRCA1, BRCA2 and PALB2). 
Patients under the unstable subtype with a high 
BRCA germline mutational burden were found to 
be better responders to platinum based therapy.
The same group later performed a larger scale, more 
comprehensive analysis including whole genome sequencing, 
copy number variation and gene expression analyses, 
histopathologic and clinical correlation, on 456 PDAC 
samples (9). In this study, 32 significantly mutated genes 
assembled in 10 molecular pathways were identified. These 
include: 
 Activating mutations of KRAS in 92%; 
 Disruption of G1/S checkpoint mechanism in 78% 
(TP53, CDKN2A, and TP53BP2); 
 TGF-B signal ing in 47% (SMAD3 ,  SMAD4 , 
TGFBR1, TGFBR2, ACVR1B and ACVR2A);
 Histone modification in 24% (KDM6A, SETD2, 
ASCOM complex members MLL2 and MLL3); 
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 The SW1/SNF complex in 14% (ARID1A, PBRM1 
and SMARCA4); 
 The BRCA pathway 5% germline and 12% somatic 
(BRCA1, BRCA2, ATM, PALB2); 
 WNT signaling defects through RNF43 mutation in 5%; 
 RNA processing genes in 16% (SF3B1, U2AF1, and 
RBM10). 
In addition, transcriptome analysis of 96 PDAC tumors 
with ≥40% epithelial cellularity revealed four different 
subtypes (9):
(I) Squamous subtype: associated with mutations in 
TP53, KDM6A, activated α6β1, α6σ4, EGF signaling, 
hypermethylation and subsequent downregulation 
of genes determining pancreatic endodermal cell 
fate. In general, gene sets involved in inflammation, 
hypoxia response, metabolic reprogramming, TGF-B 
signaling, MYC pathway activation, autophagy and 
upregulated expression of TP63(delta)N characterize 
this subtype. This subtype is associated with the worst 
survival outcomes.
(II) Pancreatic progenitor subtype: characterized by 
activated transcription factors such as PDX-1, 
that regulate differentiation from endoderm to 
pancreatic lineage, inactivating mutations of 
TGFBR2, and gene programs involved in fatty 
acid oxidation, steroid hormone biosynthesis, drug 
metabolism, and O-linked glycosylation of mucins. 
(III) Aberrantly differentiated endocrine exocrine 
(ADEX) subtype: defined by activated transcription 
factors that regulate later stages of pancreatic 
development and differentiation, including NR5A2, 
MIST1, RBPJL, INS, NEUROD1, MAFA.
(IV) Immunogenic subtype: this subtype shares many 
of the characteristics of the progenitor class, but 
is associated with significant immune infiltrate. 
Immune gene sets with a role in B- and T-cell 
signaling pathways, and antigen presentation 
delineate this subtype. Particularly upregulation of 
CTLA4 and PD1 acquired tumor response pathways 
in this subtype have therapeutic implications.
Three of the subtypes introduced by Bailey et al. directly 
overlap with Collisson subtypes presented earlier. QM-PDAC 
subtype in the Collisson study was renamed to squamous 
to better elucidate the common features of this specific 
type in PDAC with squamous type seen in other organs 
such as breast, bladder, lung, and head and neck; classical 
was renamed to pancreatic progenitor to better explain 
the presence of gene sets involved in early pancreas 
development in this subtype; and exocrine like was changed 
to ADEX to further include the endocrine differentiation in 
addition to exocrine differentiation.
Given the fact that genomic analysis of PDAC is 
frequently hampered by the sparse tumor cellularity and 
the presence of abundant stroma intermixed with normal 
endocrine and exocrine cells, Moffitt et al. performed virtual 
microdissection of 145 primary and 61 metastatic PDAC 
samples to overcome this challenge (10). In their study, they 
identified tumor-specific and stroma-specific subtypes with 
prognostic and biological relevance. Their study identified 
two stroma-specific subtypes:
(I) Activated stromal subtype: patients belonging to 
this subtype had a worse median survival time 
of 15 months and 1-year survival rate of 60% 
vs. 24 months and 80% when compared to the 
normal stromal subtype group. This subtype 
was characterized by a more diverse set of genes 
associated with macrophages, such as integrin 
ITGAM and chemokine ligands CCL13 and 
CCL18, WNT family members (WNT2 and 
WNT5A), MMP9 and MMP11, and FAP which 
has been associated with poor outcomes (11).
(II) Normal stromal subtype:  this  subtype was 
characterized by high expression of known 
markers for pancreatic stellate cells (ACTA2, 
VIM, and DES, encoding for actin, vimentin and 
desmopressin respectively).
Moffitt et al. also identified two separate tumor-specific 
subtypes, independent of normal and stromal factors:
(I) Classical tumor subtype: there was a strong overlap 
between genes of this subtype and the classical 
subtype defined by Collisson et al. earlier in this 
section (7). In concert with Collisson et al. results, 
the classical subtype in this study was also enriched 
for genes associated with GATA6 overexpression. 
In addition, SMAD4 expression was found to be 
consistently higher in this subtype consistent with 
the observation that loss of SMAD4 confers a more 
aggressive tumor phenotype.
(II) Basal-like tumor subtype: patients in this tumor 
subtype had a worse median survival time of 
11 months and 1-year survival rate of 44% 
compared to 19 months and 70% of that of classical 
tumor subtype. Despite worse prognosis, patients 
belonging to this subtype revealed a strong trend 
toward response to adjuvant therapy. Manually 
curated RNA-seq data showed that  KRAS 
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mutation encoding p.Gly12Asp was significantly 
overrepresented in this subtype.
Basal like and classical tumors were found in both the 
normal and activated stromal subtype. As expected, tumors 
from the classical subtype with normal stromal subtype had 
the best prognosis, and tumors from the basal-like subtype 
with activated stromal subtype had the worst prognosis (10).
CRC
CRC, or adenocarcinoma, is a disease with extensive 
intraclonal heterogeneity resulting in various outcomes and 
drug responses (12). However, molecular subtyping reported 
by different groups, based mainly on gene expression analysis, 
showed low consistencies, thereby posing great challenges 
in clinical translation (13-20). To reconcile these differences, 
the international CRC subtyping consortium (CRCSC) was 
formed to re-analyze 18 published datasets (N=4,151) (21). 
Four consensus molecular subtypes (CMS) were identified:
(I) CMS1; MSI immune (14%): characterized by 
hypermutated genome with few somatic copy 
number aberrations (SCNAs); encompasses the 
majority of MSI tumors and exhibits proteomic 
features suggestive of defective DNA mismatch 
repair; high frequency of BRAF  mutations; 
increased expression of genes associated with 
a diffuse immune infiltrate along with strong 
activation of immune evasion pathways. These 
features make this subtype an appropriate target 
for immune checkpoint inhibition. Clinically, 
these tumors were dominant in female patients, 
mostly presenting as right-sided lesions with 
higher histopathological grade. In terms of clinical 
outcomes, these tumors proved to have a very poor 
survival rate with every recurrence.
(II) CMS2; canonical (37%): characterized by high 
prevalence of SCNAs, and amplifications of 
transcription factor HNF4A. Gene expression 
profiling showed epithelial differentiation and 
strong upregulation of WNT and MYC downstream 
targets, both of which have been indicated in CRC 
carcinogenesis. These tumors mostly presented as 
left-sided lesions. 
(III) CMS3 (13%); metabolic: this subtype had distinct 
genomic and epigenomic features when compared 
with other chromosomal instability (CIN) subtypes 
(CMS2-4). In brief these tumors were found to have 
(i) consistently fewer SCNAs, (ii) hypermutation 
in 30% of samples, an overlap feature with CMS1 
tumors, (iii) a higher prevalence of CpG island 
methylator phenotype (CIMP)-low clusters with 
intermediate levels of genome hypermethylation. A 
high frequency of KRAS mutations were observed 
in this subtype in addition to other genes involved 
in metabolism. 
(IV) CMS4; mesenchymal (23%): gene expression 
profiling of this subtype revealed clear upregulation 
of genes involved in epithelial-to-mesenchymal 
transition (EMT), activation of transforming 
growth factor-β (TGF-β), angiogenesis, matrix 
remodeling pathways and complement associated 
inflammatory response. Clinically, these tumors 
were mostly diagnosed at more advanced stages (III/
IV). In terms of clinical outcomes, these tumors 
tended to have worse overall survival and worse 
relapse-free survival.
ESCC 
Esophageal cancer is the 8th most common cancer globally. 
ESCC is the most common histological type worldwide (1,22).
The mutational landscape of ESCC was investigated 
by Gao et al. through WES of 113 tumor-normal paired 
samples of treatment-naïve ESCC (23). The median number 
of mutations was found to be 2.9 non-silent mutations 
per megabase, far fewer than that of smoking-related 
bronchogenic carcinomas and UV-mediated melanomas. 
In addition, SCNA were found in 72% of cases. Genes 
responsible for regulating cell cycle, apoptosis, and DNA 
damage were found to be mutated in 99% of cases [TP53 
(93%), CCND1 (33%), CDKN2A (20%), NFE2L2 (10%), 
and RB1 (9%)]. Histone modifying genes were found to be 
mutated in 63% of all ESCC cases [MLL2 (19%), MLL3 
(6%), KDM6A (7%), EP300 (10%), and CREBBP (6%)]. 
The Hippo and NOTCH pathways were also frequently 
dysregulated through a number of inactivating mutations 
[FAT1-4 (27%), AJUBA (7%), NOTCH1-3 (22%) and 
FBXW7 (5%)] (23).
ESCC cases with EP300 mutation had a less favorable 
prognostic outcome when controlled for other confounders 
such as TNM staging, age, gender, smoking and drinking 
history. This mutational analysis found major similarities 
between ESCC with squamous cell carcinoma of other 
primaries (head and neck and lung squamous cell 
carcinomas), but showed considerable differences when 
compared to that of esophageal adenocarcinomas (23).
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HCC
HCC is the third cause of cancer related mortality in the 
world (22,24). In the past 10 years, considerable efforts 
have been made to segregate HCC, primarily based on 
gene expression technologies, into different prognostic 
groups (25,26). However, several factors underlie the 
heterogeneity of HCC. Epidemiologically, the incidence 
of HCC varies widely across different geographic regions, 
ancestral heritage, and genders. Furthermore, the etiologies 
of HCC differ markedly according to ancestry: chronic 
hepatitis B is the predominant cause of HCC in East 
Asia and Africa, whereas hepatitis C is more common in 
Japan and Western countries; Aflatoxin B1 exposure is 
a causative environmental factor in Asia and Africa, as 
opposed to alcohol consumption in Western countries 
(27,28). Therefore, it is reasonable to account for these 
differences in genomic analysis and subtyping of HCC. 
In a collaborative work between the International Cancer 
Genome Consortium (ICGC) and The Cancer Genome 
Atlas (TCGA) project, Totoki et al. conducted the first 
trans-ancestry HCC genome sequencing in 608 cases of 
liver cancer (503 sequenced by Totoki et al., integrated with 
105 from TCGA) (29). This cohort contained samples from 
patients with diverse ancestral backgrounds: European, US-
Asian, African-American and Japanese. Among the cohort, 
212 patients were HCV positive, 117 HBV positive, and 
150 not infected by hepatitis viruses.
The average mutation rate was found to be 2.8 
mutations per megabase. In terms of CNAs, about 29% of 
the cases showed gross chromosomal loss (average ploidy 
3.87, and the average number of CNAs was 11.58). The 
following oncogenic pathways held significance in this 
analysis:
 TP53-RB pathway. Inactivation of this pathway is a 
recurring theme in HCC tumorigenesis. TP53 and 
RB1 mutations were observed in 31% and 4.4% 
of tumors respectively. Overall 72% of cases had 
mutations in component genes of one or both of these 
pathways such as CDKN1A and CDKN2A.
 WNT pathway. Activating CTNNB1 mutations and 
inactivating mutations of AXIN1 and APC were found to 
be signatures of this pathway. Overall 66% of HCC cases 
harbor a mutation in one of the WNT pathway genes.
 Chromatin and transcription modulators. Mutations 
involved in this pathway include alterations in 
NFE2L2, and nucleosome remodelers ARID1A, 
ARID2 and BRD7.
 mTOR-PIK3CA pathway. Recurrent inactivating 
mutations in TSC1-TSC2 and activating mutations 
of PIK3CA are the signatures of this pathway. Other 
modulators such as NF1, PTEN, INPP4B and STK11 
were also mutated. In general, 45% of cases had some 
kind of alteration in the mTOR-PIK3CA pathway. 
 Interestingly, TERT (which encodes telomerase) 
promoter mutations were detected in total of 
54% of cases, with the highest frequency among 
HCV positive patients (121/188; 64%), and lower 
frequencies in non-viral and HBV positive cases, 59% 
and 37% respectively. TERT promoter mutations 
significantly co-occurred with WNT pathway gene 
mutations in HCV and non-viral cases suggesting 
a permissive oncogenic activity between the two in 
these group of patients. These findings suggest that 
TERT is a driving mutation with potential therapeutic 
targetability. Alterations of ATRX, which allows 
telomerase-independent telomere maintenance, 
have also been reported. More than 68% of patients 
had either mutations in TERT or ATRX as the most 
frequent molecular event.
In addition to the abovementioned findings, this study 
also found ancestry dependent diversity in HCC mutation 
signatures regardless of hepatitis virus status or gender (29). 
One signature featured by CTG>CAG mutations 
dominated the cases of US-Asian male and female patients, 
whereas another signature characterized by AT>AC 
mutations was frequently seen in Japanese male cases. 
These findings indicate more complicated intra- and inter-
ancestry variations and/or environmental exposures. 
GBC
GBC is a rare aggressive tumor with median survival 
time of less than 1 year (30). To further understand the 
somatic mutation spectrum in GBC, Li et al. performed a 
combined WES and ultra-deep sequencing of 57 tumor-
normal pairs of pathologically confirmed cases of GBC (31). 
Their sequencing efforts revealed TP53 and KRAS as being 
recurrently mutated, with mutation rates of 47.1% and 7.8% 
respectively. Interestingly, this study identified recurrent 
mutations in ErbB signaling pathway: ERBB1 (also known 
as EGFR) 3.9%, ERBB2 9.8%, ERBB3 11.8%, and ERBB4 
3.9%. This study showed that overexpression of each 
ERBB2 and ERBB3 mutations result in a significant increase 
in proliferation in at least one cell line when compared to 
the wild type, highlighting the role of ErbB family receptors 
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in GBC development and progression. 
In addition, Li et al. found that cases harboring one of 
the ErbB family signaling pathway mutations have worse 
prognostic outcomes in terms of overall survival when 
compared to their control counterparts (median of 8 vs. 
13 months; P=0.012) (31). These results suggest that 
patients with one of ErbB family mutations will potentially 
benefit from targeted therapies against these specific 
mutations.
Conclusions
In this article, we reviewed different subclassification 
systems proposed for each major gastrointestinal cancer 
type based on various molecular tools including next 
generation sequencing, gene expression analysis, and 
application of sophisticated analytic algorithms. Although 
these subgroups have deepened our understanding of the 
global mutational landscape and signaling aberrations of 
each cancer types, they have also posed major challenges 
and elicited important questions that need to be further 
investigated. For instance:
 How can different sub-classification systems be 
reconciled between study groups?
 How does one interpret the significant discrepancies 
in results derived from genomic, transcriptomic and 
proteomic tools to appropriately guide therapeutic 
decision making?
 What is the standardized way of preparing and 
analyzing tumor samples in order to allow accurate 
sub-classification?
 Virtually all solid cancers are clonally heterogeneous 
and constantly evolving especially under the selection 
pressure of therapeutics (32). Do cancer subtypes 
change throughout the disease course?
 Within each subclass, how can driver and passenger 
mutations be further distinguished to inform 
treatment decision?
 How could these sophisticated analyses be distilled 
down to simple, valid and reproducible assays that can 
be applied in patient care in a timely fashion?
 Do tumor specimens derived from different sites 
(primary vs. metastatic) share the same molecular 
subtype?
Numerous basic and translational research are in progress 
to improve our current understanding and fill existing 
knowledge gaps in cancer biology. The tremendous quest 
in molecular subtyping of gastrointestinal malignancies, as 
is being done in cancers from other anatomic sites, is only 
meaningful if it can truly impact patient care. Much work 
remains to be done to standardize and streamline sample 
processing, data analysis and establishment of algorithms, to 
create reproducible and reliable diagnostic tools that can be 
used in daily practice. Of equal significance, development 
of effective therapeutic agents must follow the rapid pace 
of development in molecular diagnostics. Lastly, all these 
sophisticated and costly level of work that already are the 
basis of personalized oncology must be cost-effective and 
affordable to patients. Regardless of all these challenges, 
cancer genomics has irreversibly changed our mindset 
on cancer classification as many diseases rather than one 
disease, and has revolutionized our approach towards 
individualizing treatment. 
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